恶性嗜铬细胞瘤的治疗.ppt

该【恶性嗜铬细胞瘤的治疗 】是由【88jmni97】上传分享，文档一共【35】页，该文档可以免费在线阅读，需要了解更多关于【恶性嗜铬细胞瘤的治疗 】的内容，可以使用淘豆网的站内搜索功能，选择自己适合的文档，以下文字是截取该文章内的部分文字，如需要获得完整电子版，请下载此文档到您的设备，方便您编辑和打印。2025/2/11
1
Literature Report
Therapy of Malignant Pheochromocytoma恶性嗜铬细胞瘤的治疗
汇报时间：xx月xx日
2022
Anuanl Work Summary Report
Let's make a summary together!
rule of 10s for pheochromocytoma (PCC)
10% bilateral
10% extra-adrenal
10% extra-abdomen
10% malignant
10% familial
10% children
10% normal blood pressure
The most frequent site of metastases is the skeleton
Additional sites are liver, retroperitoneum with lymph nodes, CNS, pleura, and kidney
Currently, there is no effective cure for malignant pheochromocytoma.
There are also no reliable histopathological methods for distinguishing benign from malignant tumors.
Malignancy requires evidence of metastases at non-chromaffin sites distant from that of the primary tumor.
Metastatic disease in pheochromocytoma may be present at the time of initial diagnosis or may only became evident after surgical removal of the primary tumor, usually within 5 years, but sometimes 16 or more years later.
Due to the rarity of the tumor, clinical studies about pheochromocytoma suffer from a fragmented nature and usually involve too small a number of cases to reach conclusive results.
Because there is currently no effective cure for malignant pheochromocytoma, most treatment are palliative, but in some cases may reduce tumor burden and prolong survival.
Without treatment, the 5-year survival is generally less than 50%.
The course, however, can be highly variable with occasional patients living more than 20 years after diagnosis.
01
03
02
Once malignancy is diagnosed, therapy is generally directed at controlling blood pressure, but may also include tumor debulking.
Surgery
Radiopharmaceuticals
Combined Chemotherapy
Arterial Embolization
Surgery
Radiopharmaceuticals
Combined Chemotherapy
Arterial Embolization